CRISPR Therapeutics AG (NASDAQ:CRSP) shares, rose in value on Friday, June 11, with the stock price up by 1.92% to the previous day’s close as strong demand from buyers drove the stock to $126.09.
Actively observing the price movement in the recent trading, the stock is buoying the session at $123.71, falling within a range of $118.32 and $124.15. Referring to stock’s 52-week performance, its high was $220.20, and the low was $58.02. On the whole, CRSP has fluctuated by 19.48% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $3.52, which is expected to increase to $7.39 for fiscal year -$0.51 and then to about -$6.32 by fiscal year 2022. Data indicates that the EPS growth is expected to be 90.40% in 2022, while the next year’s EPS growth is forecast to be -1,139.20%.
According to the average forecast, sales growth in current quarter could jump up 2,223.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $465.43 million, representing an increase of 64,633.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CRSP’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
21 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 5 analyst(s), 14 recommend it as a Buy and 0 called the CRSP stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CRSP currently trading nearly 9.85% and 7.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 62.37, while the 7-day volatility ratio is showing 4.94% which for the 30-day chart, stands at 4.81%. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.26, and its average true range (ATR) is 6.05. The company’s stock has been forecasted to trade at an average price of $158.83 over the course of the next 52 weeks, with a low of $55.00 and a high of $220.00. Based on these price targets, the low is 56.38% off current price, whereas the price has to move -74.48% to reach the yearly target high. Additionally, analysts’ median price of $165.00 is likely to be welcomed by investors because it represents a decrease of -30.86% from the current levels.
A comparison of CRISPR Therapeutics AG (CRSP) with its peers suggests the former has fared considerably weaker in the market. CRSP showed an intraday change of 1.92% in today’s session so far, and over the past year, it grew by 96.27%%. In comparison, Pieris Pharmaceuticals Inc. (PIRS) has moved higher at 1.12% today and is up 10.15% over the past 12 months.
Data on historical trading for CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the trading volumes over the past 10 days have averaged 0.93 million and over the past 3 months, they’ve averaged 1.40 million. According to company’s latest data on outstanding shares, there are 75.00 million shares outstanding.
Nearly 0.40% of CRISPR Therapeutics AG’s shares belong to company insiders and institutional investors own 58.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.32 million shares as on May 27, 2021, resulting in a short ratio of 2.47. According to the data, the short interest in CRISPR Therapeutics AG (CRSP) stood at 4.38% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 3.46 million. The stock has fallen by -19.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRSP stock heading into the next quarter.